期刊文献+

硼替佐米对淋巴瘤细胞系CA46的作用及机制研究

Effect of Bortezomib on Lymphoma Cell Line CA46 and Its Relative Mechanisms
下载PDF
导出
摘要 本研究探讨硼替佐米(bortezomib,BZM)对淋巴瘤细胞系CA46的作用及相关机制。采用MTT法观察BZM对CA46细胞增殖的作用,流式细胞术分析BZM对CA46细胞凋亡的影响,Western blot法检测经BZM作用的CA46细胞procaspase-3、BCL-2蛋白表达水平。结果表明,BZM能明显抑制CA46细胞增殖,24小时和48小时的半数抑制浓度(IC50)分别为53.19,19.68nmol/L;BZM能诱导CA46细胞凋亡,且呈现剂量和时间依赖性;20nmol/LBZM处理CA46细胞不同时间后procaspase-3、BCL-2蛋白表达呈时间依赖性降低。结论:BZM可以抑制CA46细胞增殖,诱导其凋亡,其机制可能涉及了BCL-2表达下调及caspase-3的活化。 The objective of this study was to explore the effect of bortezomib (BZM) on lymphoma cell line CA46 and its relative mechanisms in vitro. The effects of BZM on the proliferation and apoptosis of CA46 cells were assayed by MTT method and flow cytometry respectively. The effect of BZM on the expression levels of procaspase-3 and BCL- 2 protein were detected by Western blot. The results indicated that the BZM could inhibit the growth of CA46 cells significantly and the concentration of 50% growth inhibition ( ICs0 ) at 24 and 48 hours were 53.19 and 19.68 nmol/L respectively. After treatment with 20,40,80 nmol/L BZM for 24, 48 and 72 hours, a dose- and time-dependent apoptosis of CA46 cells could be observed. After treatment with 20 nmol/L BZM at different time point, a time-dependent reduction of procaspase-3 and BCL-2 protein expression in CA46 cells was found. It is concluded that the BZM can inhibit the proliferation and induce the apoptosis of CA46 cells, which relative mechanism may involve the reduction of BCL-2 and the activation of caspase 3.
出处 《中国实验血液学杂志》 CAS CSCD 2010年第4期919-922,共4页 Journal of Experimental Hematology
基金 福建省自然科学基金资助,编号2009J01143
关键词 硼替佐米 淋巴瘤 CA46细胞系 细胞增殖 细胞凋亡 bortezomib lymphoma CA46 cell line cell profiferation cell apoptosis
  • 相关文献

参考文献9

  • 1Fribley A, Wang CY. Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress. Cancer Biol Ther, 2006 ;5 (7) :745 -748.
  • 2Voorhees PM, Dees EC, O'Neil B, et al. The proteasome as a target for cancer therapy. Clin Cancer Res, 2003 ;9 (17) :6316 - 6325.
  • 3Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS- 341. Blood, 2003;101(4): 1530 -1534.
  • 4Cheriyath V, Jacobs BS, Hussein MA. Proteasome inhibltors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors. Drugs R D ,2007 ;8 ( 1 ) : 1 - 12.
  • 5Mitsiades CS, Mitsiades NS, Munshi NC, et al. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer, 2006 ;42 ( 11 ) : 1564 - 1573.
  • 6Shi J, Tricot GJ, Garg TK, et al. Bortezomib down-regulates the cell-surface expression of HLA class Ⅰ and enhances natural killer cell-mediated lysis of myeloma. Blood, 2008 ; 111 (3) : 1309 - 1317.
  • 7Einsele H. Bortezomib. Recent Results. Cancer Res, 2010;184: 173 - 187.
  • 8O'Connor OA, Portloek C, Moskowitz C,et al. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res, 2010;16(2) :719 -726.
  • 9Di Bella N, Taetle R, Kolibaba K,et al. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood, 2010;115(3) :475 -480.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部